Berberin bei Atherosklerose – Verbesserung des Lipidprofils der Endothelfunktion

Zusammenfassung

Atherosklerose ist eine multifaktorelle Gefäßerkrankung, verursacht durch Fettstoffwechselstörungen, chronische Entzündungsprozesse des Gefäßendothels, Plaquebildung mit Stenosen und thrombotischen Prozessen, induziert durch Plaquerupturen. In letzter Zeit verdichten sich mehr und mehr Erkenntnisse über die therapeutische Wirkung von Berberin bei Atherosklerose: Verbesserung der mitochondrialen Funktion, Verhinderung von Oxidationsprozessen im Gefäßendothel sowie entzündungshemmende Wirkungen. Darüber hinaus ergeben sich neue Erkenntnisse hinsichtlich antiatherogener Effekte durch eine Induktion der Autophagie und einer Reduktion des PCSK9-Spiegels. Der folgende Artikel stellt einen neuen Kandidaten für den Schutz vor Atherosklerose durch Verbesserung des Lipidprofils und der Endothelfunktion der Koronargefäße vor.

Abstract

Atherosclerosis is a multifactorial vascular disease caused by dyslipidemia, chronic inflammatory processes of the vascular endothelium, plaque formation with stenoses, and thrombotic processes induced by plaque ruptures. Recently, there has been more and more evidence regarding the therapeutic effects of berberine in atherosclerosis: improvement of the mitochondrial function, prevention of oxidation processes in the vascular endothelium as well as anti-inflammatory effects. In addition, there is new evidence with respect to antiatherogenic effects through an induction of autophagy and a reduction of the PCSK9 level. The following article presents a new candidate for the protection against atherosclerosis by improving the lipid profile and endothelial function of coronary vessels.

Schlüsselwörter

Berberin - Atherosklerose - Autophagie - Lipidprofil - PCSK9-Spiegel

Key words

Berberine - atherosclerosis - autophagy - lipid profile - PCSK9 level

Publikationsverlauf

Artikel online veröffentlicht:
12. Oktober 2021

• Literatur

• 1 Hiller K, Melzig MF. Lexikon der Arzneipflanzen und Drogen in zwei Bänden. 1. Band. Heidelberg, Berlin: Spektrum; 1999: 104
• 2 Hu Y, Ehli E, Kittelsrud J. et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine 2012; 19 (10) 861-873
• 3 Lee T-S, Pan CC, Peng CC. et al. Anti-atherogenic effect of berberine on LXRα-ABCA1-dependent cholesterol efflux in macrophages. J Cell Biochem 2010; 111: 104-110
• 4 Wang Q, Zhang M, Liang B. et al. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: The role of uncoupling protein 2. PLoS ONE 2011; 6: e25436
• 5 Hu Y, Davies GE. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia 2010; 81: 358-366
• 6 Li H, Dong B, Park SW. et al. Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009; 284: 28885-28895
• 7 Dubuc G, Chamberland A, Wassef H. et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptose-regulated convertase-1 implicated in familial hypercholesterilemia. Aterioscler Vasc Biol 2004; 24: 454-459
• 8 Schmandke H. Berberin, ein Isochinolinalkaloid der Berberitze, mit blutglukose-und lipidsenkender Wirkung. Ernährungsumschau 2007; 54: 570-573
• 9 Kumar A, Ekavali CK, Mukherjee M. et al. Current knowledge and pharmacological profile of berberine: An update. Eur J Pharmacol 2015; 761: 288-297
• 10 Yao J, Kong W, Jiang J. Learning from berberine: Treating chronic diseases through multiple targets. Sci China Life Sci 2015; 58 (09) 854-859
• 11 Ren G, Guo JH, Qian YZ. et al. Berberine improves glucose and lipid metabolism in HepG2 cells through AMPKα activation. Front Pharmacol 2020; 11: 647
• 12 Kong W, Wei J, Abidi P. et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344-1351
• 13 Li H, Dong B, Park SW. et al. Hepatocyte nuclear factor 1α plays a critical role in PCSK) gene transcription and regulation by the natural hypercholemic compound Berberine. J Boil Chem 2009; 284: 28885-28895
• 14 Jia YJ, Xu RX, Sun J. Enhanced circulating PCSK) concentration by berberine through SREBP-2 pathway in high-feed rats. J Transl Med 2014; 12: 103
• 15 Liu DL, Xu LJ, Dong H. et al. Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chin J Integr Med 2014; 21: 132-138
• 16 Dong H, Zhao Y, Zhao L. et al. The effect of berberine on blood lipids: A systemic review and meta-analysis of randomized controlled trials. Planta Med 2013; 79 (06) 437-446
• 17 Ling MY, Ma ZY, Wang YY. et al. Up-regulated ATP-sensitive potassium channels play a role in increased inflammation and plaque vulnerability in macrophages. Atherosclerosis 2013; 226: 348-355
• 18 Fan X, Wang J, Hou J. et al. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. J Transl Med 2015; 13: 92
• 19 Zhou M, Deng Y, Liu M. et al. The pharmacological activity of Berberine, a review for liver protection. Eur J Pharmacol 2020; 14: 173655
• 20 Song D, Hao J, Fan D. Biological properties and clinical applications of Berberine. Front Med 2020; 14 (05) 564-582
• 21 Tan W, Wang Y, Wang K. et al. Improvement of endothel dysfunction of Berberine in atherosclerotic mice and mechanism exploring through TMT-based proteomics. Oxid Med Cell Longev 2020; 8683404
• 22 Orr ST, Ripp SL, Ballard TE. et al. Mechanism-based inactivation (MBI) of cytochrome p450 enzymes: Structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 2012; 55: 4896-4933
• 23 Lyu Y, Zhang Y, Yang M. et al. Pharmacocinetic interactions between Metformin and Berberine in rats: Role of oral administration sequences and microbiota. Life Sci 2019; 235: 116818